Pharma/fine chemicals roundup—26 February
8:07 AM MST | February 26, 2013 | By DEEPTI RAMESH
Informex 2013: Bright outlook for US API manufacturing
Drug companies looking for speedy turnaround and strong intellectual property (IP) protection for active pharmaceutical ingredient (API) production are moving away from low-cost emerging market firms, lifting prospects for US-based producers, according to attendees of Informex, at Anaheim, CA, last week. Executives said they are seeing more situations where clients feel as though the risk level to bringing the final stages of API production to Asia is too high and are bringing later-phase activities back to the United States, where IP protection is more certain.
BASF and Bend Research collaborate to improve solubility and bioavailability of drugs
BASF says that it has signed an agreement with Bend Research (Bend, OR) to jointly evaluate and develop novel excipients to enhance the solubility and bioavailability of poorly soluble drugs. Bioavailability is the measure of the amount of drug that is actually absorbed from a given dose. BASF and Bend Research plan to combine their expertise in the development of new excipients and drug formulations to provide customers from the pharmaceutical industry with early access to the latest polymer innovations. The aim of this collaboration is to meet increasing challenges of poorly soluble active pharmaceutical ingredients (APIs)—BCS Class II and IV compounds. The initial focus will be on optimizing new vinylpyrrolidone-based copolymers being developed for the solubilization of poorly soluble APIs.
DSM and Chemtrix join forces for continuous flow chemistry in API manufacturing
DSM Pharmaceutical Products (Parsippany, NJ), the custom manufacturing and technology business of DSM, says it has signed a collaboration agreement with Chemtrix (Geleen, Netherlands) in the field of continuous flow chemistry to provide sustainable equipment, and development and manufacturing services to the pharmaceutical industry. The agreement brings together the expertise of both companies in continuous flow chemistry to serve the pharmaceutical industry with processes for the development and manufacture of active pharmaceutical ingredients (APIs), which require new technologies to increase sustainability, reduce energy consumption, and provide benefits for cost of goods, DSM says.
China cracks down on counterfeit drugs
The Chinese government says that the State Food and Drug Administration (SFDA; Beijing) and the Ministry of Public Security (MPS; Beijing) jointly took action against more than 20,000 suspects in 2012 for making and selling counterfeit medicines. The suspects were involved in about 14,000 cases of counterfeit medicines that had a total value of over 16 billion renminbi ($2.56 billion), according to a statement jointly released by SFDA and MPS, the government says. Twenty-eight companies were shut down and 228 suspects were arrested for making capsules and gelatin products containing excessive chromium last year, the government says.
IMCD acquires Indian pharma ingredients distributor Indchem International
Distributor IMCD (Rotterdam) has acquired Indchem International (Mumbai), an established player in the Indian pharma ingredients market. Indchem has represented a number of major excipient manufacturers over the last two decades with a goal of providing Indian pharmaceutical industry with a wide range of excipients and reducing their clients’ formulation complexities.
Connect with IHS Chemical Week
Our related sites